Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
AML
•
Hematology
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
